31
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, SARS-CoV-2 infection is associated with marked lymphopenia that correlates with morbidity and mortality [1, 2]. Here, we present the first report on serial immunophenotypic and functional changes in 13 consecutively recruited patients infected with SARS-CoV-2 virus during their first week of ICU stay (Supplementary Table 1) with 10 healthy donors used as controls. Patients uniformly exhibited deep global and persisting T, NK and B cell lymphopenia from ICU admission (D0) to day 7 (D7) (Fig. 1a to d). On D0, median absolute lymphocyte count was dramatically reduced at 0.72 [0.65–0.88] G/L as were CD4 and CD8 T cell counts at 0.29 [0.19–0.43] and 0.08 [0.05–0.1] G/L (Fig. 1a, e, f), such CD4 T cell levels reflecting profound immunosuppression in HIV-infected patients. Few CD4 T cells transiently expressed CTLA-4 during the first 3 days (Fig. 1g) while expression of PD-1 was observed at D0 and increased until D7 (Fig. 1h). CD8 T cells significantly and persistently expressed PD-1 from D0 to D7 while CTLA-4 expression remained unchanged (Fig. 1i, j). Fig. 1 Over time, ICU COVID-19 patients showed a profound and sustained lymphopenia correlated with increased percentages of CD4 and CD8 expressing exhaustion marks and increased frequency of immune suppressive cells. Box plot represent results for 10 healthy subjects (controls) and for the following time point and number of COVID-19 ICU patients. The number of patients is given below the horizontal axis of panel a. Boxes give the median with the first and the third quartile. Whiskers represent min to max. Lines with bracket and plain lines indicate a Mann–Whitney and ANOVA (Kruskall–Wallis test) comparison with controls or during the ICU stay respectively. Test p values are represented by *, ** and *** for p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001 respectively. Upper panel a, b, c, d, e, f: absolute lymphocytes count (ALC) (a), CD3 T-lymphocytes (b), Natural Killer (NK) cells (c), B lymphocytes (d), CD4 (e) and CD8 T cells (f). Light blue boxes represent controls and darker blue boxes represent patients. Middle panel g, h, i, j: percentages of CD4 (g and h) and CD8 (i and j) T cells expressing CTLA-4 (g and i) and PD-1 (h and j). Light green boxes represent controls and darker green boxes represent patients. Lower panel k, l, m, n, o: percentages of CD4 +/CD25 +/CD127low regulatory T cells (T-reg) [3] (k) expressing CTLA-4 (l) and PD-1 (m) and CD14 monocyte counts (n) with quantification of the mHLA-DR at their surface membrane (o). Light orange boxes represent controls and darker orange boxes represent patients Being heterogeneous at D0 (Fig. 1k), percentages of regulatory T cells (Tregs) increased during time. Few of them over-expressed CTLA-4 while PD-1 expression was strongly and stably increased until D7 (Fig. 1l, m). Total granulocytes were moderately increased with a transient egression of immature granulocytes in 4/10 patients at day 4–5 (Supplementary Figure 1). Monocyte counts increased during the first week. Nevertheless, HLA-DR expression was strongly down-regulated by a threefold factor at D0. Strikingly this decrease persisted unabated until D7, possibly impairing antigen presentation, and was associated with increased PD-L1 expression (Fig. 1n, o and Supplementary Figure 4d). Being either an exhaustion or an activation marker, PD-1 is an inducer of CD8 T cell apoptosis when activated. Therefore, functional evaluation of T-lymphocytes was performed in three patients and controls for comparison. Meanwhile production of TNF-α and IL-2 was normal, CD4 T cell IFN-γ production was decreased (Supplementary Figure 2), indicating a CD4 exhaustion process. In contrast, CD8 T cells could be involved in anti-viral immune response since they produced higher levels of IFN-γ and TNF-α (Supplementary Figure 3). Consistently, percentages of effector CD4 T cells were decreased while those of effector memory and activated CD8 T cells were increased (Supplementary Figure 4a to 4c). Circulating levels of IL-6 and IL-8 were moderately but significantly and sustainly increased over time, reflecting the known SARS-CoV-2 related sub-acute inflammatory response of innate immune cells [4] (Supplementary Figure 5). Although our results warrant further confirmation in larger cohort, they strongly suggest a multifaceted devastating effect of the virus to cause depletion of virtually all classes of adaptive immune cells and to cause upregulation of potent T cell killing and immunosuppressive mechanisms in critically-ill COVID-19 patients. Since T cells are essential for definitive viral clearance, these results call into question therapies (e.g., anti-IL-6, corticosteroids, JAK inhibitors) that aim to block the ability of the patient to mount an effective immune response to the invading SARS-CoV-2. Knowing that almost all anti-inflammatory therapies have also chronically failed in sepsis, consideration to therapies that boost host immunity in selected severe ARDS ICU patients (e.g., IL-7, IFN-γ or checkpoint inhibitors) may be appropriate [5, 6]. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 229 kb) Supplementary material 2 (PDF 551 kb)

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The many faces of the anti-COVID immune response

          This Perspective explores the contributions of the innate and adaptive immune systems to both viral control as well as toxicity during COVID-19 infections and offers suggestions to both understand and therapeutically modulate anti-COVID immunity.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial

            BACKGROUND. A defining pathophysiologic feature of sepsis is profound apoptosis-induced death and depletion of CD4 + and CD8 + T cells. Interleukin-7 (IL-7) is an antiapoptotic common γ-chain cytokine that is essential for lymphocyte proliferation and survival. Clinical trials of IL-7 in over 390 oncologic and lymphopenic patients showed that IL-7 was safe, invariably increased CD4 + and CD8 + lymphocyte counts, and improved immunity. METHODS. We conducted a prospective, randomized, double-blind, placebo-controlled trial of recombinant human IL-7 (CYT107) in patients with septic shock and severe lymphopenia. Twenty-seven patients at academic sites in France and the United States received CYT107 or placebo for 4 weeks. Primary aims were to determine the safety of CYT107 in sepsis and its ability to reverse lymphopenia. RESULTS. CYT107 was well tolerated without evidence of inducing cytokine storm or worsening inflammation or organ dysfunction. CYT107 caused a 3- to 4-fold increase in absolute lymphocyte counts and in circulating CD4 + and CD8 + T cells that persisted for weeks after drug administration. CYT107 also increased T cell proliferation and activation. CONCLUSIONS. This is the first trial of an immunoadjuvant therapy targeting defects in adaptive immunity in patients with sepsis. CYT107 reversed the marked loss of CD4 + and CD8 + immune effector cells, a hallmark of sepsis and a likely key mechanism in its morbidity and mortality. CYT107 represents a potential new way forward in the treatment of patients with sepsis by restoring adaptive immunity. Such immune-based therapy should be broadly protective against diverse pathogens including multidrug resistant bacteria that preferentially target patients with impaired immunity. TRIAL REGISTRATION. Trials registered at clinicaltrials.gov: NCT02640807 and NCT02797431. FUNDING. Revimmune, NIH National Institute of General Medical Sciences GM44118. Interleukin-7 administration to patients in septic shock with severe lymphopenia was well tolerated and increased CD4 and CD8 T cells.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              CD4+CD25+CD127- assessment as a surrogate phenotype for FOXP3+ regulatory T cells in HIV-1 infected viremic and aviremic subjects.

              Although likely pivotal, the role of regulatory T cells (Tregs) in HIV pathogenesis remains elusive. This can be partly explained by analytical issues regarding their phenotypic identification in clinical studies. Instead of intracellular FOXP3 staining, CD4+CD25+CD127- phenotype has been proposed as an alternative to identify Tregs in clinical samples. However, its use remains controversial in viremic patients. Therefore, the objective of the present study was to assess the correlation between frequencies of CD4+CD25+CD127- and CD4+CD25+FOXP3+ lymphocytes in viremic and matched aviremic HIV-infected patients. Peripheral blood was collected from HIV-1 infected patients. Eleven viremic patients (Viral Load > 40 copies/mL) were matched (age, sex, CD4+ cell number) with 8 aviremic patients under highly active antiretroviral therapy (HAART). Fresh whole blood was immediately stained to analyze by flow cytometry the correlation between CD4+CD25+CD127- and the reference phenotype CD4+CD25+FOXP3+ lymphocytes in the same tube (four color staining CD4/CD25/CD127/FOXP3 for concomitant analysis of cell surface and intracellular markers). In both groups, no significant differences were observed when comparing CD4+CD25+CD127- and CD4+CD25+FOXP3+ cell frequencies. In line, a strong correlation between CD4+CD25+CD127- and CD4+CD25+FOXP3+ lymphocyte percentages was observed in the whole patient population (r: 0.948, P < 0.001) or each group separately: aviremic (r: 0.968, P < 0.001), viremic (r: 0.9, P < 0.001). Finally, we found that most CD4+FOXP3+ cells were indeed CD25+CD127-, both in viremic and aviremic groups (88.5% and 90.9%, respectively). We observed that CD4+CD25+CD127- phenotype is a good and easy-to-perform surrogate identification strategy for FOXP3+ regulatory T cells in both viremic and aviremic HIV-1-infected subjects. Thus, it represents a useful tool for monitoring Tregs in clinical research studies based on large cohorts of patients prospectively monitored, including HIV-infected subjects. Copyright © 2012 International Clinical Cytometry Society.
                Bookmark

                Author and article information

                Contributors
                b.francois@unilim.fr
                Journal
                Intensive Care Med
                Intensive Care Med
                Intensive Care Medicine
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0342-4642
                1432-1238
                8 June 2020
                : 1-3
                Affiliations
                [1 ]GRID grid.9966.0, ISNI 0000 0001 2165 4861, UMR CNRS 7276, INSERM 1262, Faculty of Medicine, , University of Limoges, ; 87000 Limoges, France
                [2 ]GRID grid.412212.6, ISNI 0000 0001 1481 5225, Inserm CIC 1435 & UMR 1092, , Dupuytren Teaching Hospital, ; 87000 Limoges, France
                [3 ]GRID grid.412212.6, ISNI 0000 0001 1481 5225, Medical-Surgical Intensive Care Unit, , Dupuytren Teaching Hospital, ; 87000 Limoges, France
                [4 ]GRID grid.412212.6, ISNI 0000 0001 1481 5225, Laboratory of Hematology, , Dupuytren Teaching Hospital, ; 87000 Limoges, France
                [5 ]GRID grid.412212.6, ISNI 0000 0001 1481 5225, Réanimation Polyvalente, , CHU Dupuytren, ; 2 Avenue Martin-Luther King, 87042 Limoges, France
                Author information
                http://orcid.org/0000-0002-5170-736X
                http://orcid.org/0000-0002-3474-7247
                http://orcid.org/0000-0002-2531-1652
                Article
                6127
                10.1007/s00134-020-06127-x
                7276497
                32514592
                ca8230a0-a919-4b29-a2b3-3e91536064ed
                © Springer-Verlag GmbH Germany, part of Springer Nature 2020

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 19 May 2020
                Categories
                Letter

                Emergency medicine & Trauma
                Emergency medicine & Trauma

                Comments

                Comment on this article